Rigel completes enrollment of FIT phase 3 program for fostamatinib in ITP
The first study in this program completed enrollment at the end of January and the second study has now completed enrollment. The results from the first study are
OZMOSI and Planview have formed a partnership to support pharmaceutical organisations by integrating Ozmosi’s structured, machine-readable clinical datasets with Planview’s AI-driven portfolio planning platform.
Based upon the documented relationship of P450 and certain potential drug-drug interactions, this positive data is central to the planned Phase 2 clinical trial where Kevetrin will be
VI Partners and High-Tech Gründerfonds also participated in the round which will help progress Amal’s cancer vaccines. Amal Therapeutics is a Swiss biotech company developing and progressing therapeutic